Status:
UNKNOWN
Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With Sciatica
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Clinical, psychophysical, behavioral or genetic factor will predict the response to opioid treatment in patients with chronic neuropathic pain.
Eligibility Criteria
Inclusion
- Patients with moderate to severe chronic neuropathic pain or patients with radiculitis between 18 and 75 years of age.
- Candidates for chronic opioid therapy for nonmalignant pain as determined by treating physician.
- Patients treated with non-opioid analgetics, anti- inflammatory drugs or low opioid dosage (\< 30 mg of oral morphine-equivalents per day).
- Ability to understand the purpose and instructions of the study and to sign an informed consent.
- \-
Exclusion
- Diabetic Neuropathy 2.Pain in upper limbs 3.Receiving anti- depressants and/or anticonvulsants 4.Pregnant women 5.Inability to comply with study protocol. 6.Allergy to Opioids 7.A diagnosis of Raynaud's Syndrome 8.History of substance abuse
- \-
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01914042
Start Date
July 1 2013
End Date
December 1 2019
Last Update
April 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Health Care Campus
Haifa, Israel, 31096